The NPM1 mutation, typically a favorable prognostic marker in newly diagnosed AML, loses this advantage in the relapsed/refractory setting. Survival for relapsed NPM1 patients becomes as poor as for those without the mutation, justifying aggressive targeted therapy with menin inhibitors.

A major limitation of menin inhibitor monotherapy is acquired resistance. Up to 39% of patients on revumenib develop mutations in the menin (MEN1) gene. These mutations prevent the drug from binding to its target, leading to rapid relapse and highlighting the need for combination therapies or next-generation agents.

Despite clinical efficacy, menin inhibitor monotherapy provides a relatively short duration of response (4-6 months) in the relapsed/refractory setting. Their main clinical benefit is achieving a deep enough remission to allow patients to proceed to a potentially curative allogeneic stem cell transplant.

Subgroup analyses of menin inhibitor trials reveal a key difference for treatment sequencing. Patients with prior venetoclax exposure showed lower response rates to Revumenitib. In contrast, early data for Ziftomenib suggests prior venetoclax use did not negatively impact its efficacy.

When an AML patient presents with multiple targetable mutations (FLT3, NPM1, IDH), clinicians follow a treatment hierarchy. FLT3-targeted therapy is typically the first choice due to its aggressive phenotype. Menin inhibitors for NPM1 are next, followed by IDH inhibitors, guiding treatment decisions in complex cases.

A high-sensitivity NGS assay for cell-free DNA (cfDNA) can detect emerging resistance mutations in the MEN1 gene. This allows for early identification of treatment failure, potentially months before a patient shows clinical signs of relapse, opening a window for proactive therapeutic adjustments like switching inhibitors.

The new menin inhibitor, enzomenib, demonstrates potentially superior response rates (CR/CRH of 40-60%) compared to existing agents (~23%). Crucially, early data shows no QTc prolongation, a significant dose-limiting toxicity for current menin inhibitors, suggesting a major safety improvement for this drug class.

Post-transplant maintenance strategy differs by mutation. For high-risk KMT2A-rearranged AML with less sensitive monitoring, maintenance is strongly considered. For NPM1-mutated AML, clinicians rely on highly sensitive qPCR for Minimal Residual Disease (MRD); if a patient is MRD-negative, they often forgo maintenance therapy.

The Spanish KIWI trial showed a surprising survival benefit for quizartinib in FLT3-ITD negative AML. The benefit was greatest in patients with NPM1 and DNMT3A mutations, suggesting the drug's efficacy extends beyond its primary target through other mechanisms.